Commentary

Video

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

Author(s):

Vijayakrishna Gadi, MD, University of Illinois College of MedicineMegan Kruse, MD, of Cleveland Clinic

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Related Videos
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Arya Mariam Roy, MBBS
Suneel Kamath, MD
Julia Foldi, MD, PhD
Suneel Kamath, MD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
VK Gadi, MD, PhD
Related Content
Karthik V. Giridhar, MD
June 12th 2024

Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Erika Hamilton, MD, of Sarah Cannon Research Institute
June 5th 2024

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

Lydia Pace, MD, MPH
June 5th 2024

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer